3,472 Shares in Becton, Dickinson and Company $BDX Bought by Diversify Advisory Services LLC

Diversify Advisory Services LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX) in the second quarter, HoldingsChannel reports. The fund bought 3,472 shares of the medical instruments supplier’s stock, valued at approximately $552,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BDX. Auto Owners Insurance Co boosted its stake in shares of Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after buying an additional 40,528,680 shares during the last quarter. BlackRock Inc. bought a new stake in Becton, Dickinson and Company during the second quarter worth about $3,721,533,000. Wellington Management Group LLP raised its holdings in Becton, Dickinson and Company by 9,056.3% during the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after acquiring an additional 5,174,944 shares in the last quarter. Vanguard Group Inc. boosted its position in Becton, Dickinson and Company by 13.0% during the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after purchasing an additional 4,223,149 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its stake in Becton, Dickinson and Company by 23,219.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after purchasing an additional 4,137,888 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Up 0.1%

Shares of BDX stock opened at $187.79 on Friday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $190.01. The company has a market capitalization of $51.74 billion, a PE ratio of 56.56, a price-to-earnings-growth ratio of 13.22 and a beta of 0.19. The firm has a 50 day moving average price of $160.66 and a two-hundred day moving average price of $160.91. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. This trade represents a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 11,779 shares of company stock valued at $1,974,669. 0.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BDX shares. Royal Bank Of Canada boosted their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research report on Thursday, August 13th. Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. Piper Sandler upped their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. TD Cowen increased their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Finally, Bank of America lowered their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.